Epstein-barr virus-positive diffuse large B-cell lymphoma during therapy with alemtuzumab for T-cell prolymphocytic leukemia

J Clin Oncol. 2010 Feb 10;28(5):e69-72. doi: 10.1200/JCO.2009.24.4194. Epub 2009 Nov 16.

Authors

Aliyah R Sohani¹, Judith A Ferry, Priscilla S Chang, Jeremy S Abramson

Affiliation

¹ Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.

PMID: 19917859
DOI: 10.1200/JCO.2009.24.4194

No abstract available

Publication types

Case Reports

MeSH terms

Alemtuzumab
Antibodies, Monoclonal / adverse effects*
Antibodies, Monoclonal, Humanized
Antibodies, Neoplasm / adverse effects*
Antineoplastic Agents / adverse effects*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Bone Marrow Examination
Disease Progression
Fatal Outcome
Female
Herpesvirus 4, Human / isolation & purification*
Humans
Leukemia, Prolymphocytic, T-Cell / drug therapy*
Leukemia, Prolymphocytic, T-Cell / pathology
Lymphoma, Large B-Cell, Diffuse / chemically induced*
Lymphoma, Large B-Cell, Diffuse / drug therapy
Lymphoma, Large B-Cell, Diffuse / immunology
Lymphoma, Large B-Cell, Diffuse / pathology
Lymphoma, Large B-Cell, Diffuse / virology
Magnetic Resonance Imaging
Middle Aged
Treatment Failure

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antibodies, Neoplasm
Antineoplastic Agents
Alemtuzumab